Marc Stapley

Chief Executive Officer at Veracyte, Inc.

Marc Stapley is the Chief Executive Officer of Veracyte, Inc., a position he has held since June 1, 2021.1 2 He also serves on the company's board of directors.

Career Background

Stapley has extensive experience in the genomic diagnostics industry:

Prior to joining Veracyte, he was Chairman and CEO of Helix, a leading population genomics company, from April 2019 to May 2021.1
Before Helix, Stapley held key executive leadership positions at Illumina, the global leader in DNA sequencing technologies, for seven years. His roles included Chief Financial Officer, Chief Administrative Officer, and Executive Vice President.1 2
Earlier in his career, he served as Senior Vice President of Finance at Pfizer Inc.1
He has also held senior finance roles at companies like Alcatel-Lucent, Cadence Design Systems, Inc., and Coopers & Lybrand (now PwC).1

Education and Qualifications

Stapley holds a B.Sc. (Honors) in Mathematics from The University of Reading in England.1 2
He is a member of the Institute of Chartered Accountants in England and Wales.1

Current Roles and Responsibilities

As CEO of Veracyte, Stapley leads the company's strategic focus on providing molecular diagnostics technology throughout the cancer care cycle.3 Under his leadership, Veracyte has:

Expanded its portfolio through acquisitions, such as C2i Genomics, to cover more aspects of cancer diagnosis and treatment monitoring.3
Continued to invest in AI and machine learning technologies to enhance their diagnostic capabilities.3

Board Memberships

In addition to his role at Veracyte, Stapley serves on the board of directors for:

Helix
Glaukos Corporation (GKOS)1 4

Marc Stapley's leadership and extensive experience in the genomics and diagnostics fields position him well to guide Veracyte's growth and innovation in molecular diagnostics and precision medicine.